Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
03 10 2019
Historique:
received: 16 08 2018
revised: 03 10 2018
accepted: 15 10 2018
pubmed: 21 11 2018
medline: 16 4 2020
entrez: 21 11 2018
Statut: ppublish

Résumé

Rabies causes 60,000 deaths worldwide annually. Rabies post-exposure prophylaxis is highly effective but often geographically and financially beyond reach in endemic developing countries. We conducted a retrospective study on clinical outcome at ≥6 months in 3318 Cambodians who received intradermal Vero cell vaccine post-exposure prophylaxis after a bite by a rabid or sick-looking but untested dog in 2003-2014. An external expert panel examined verbal autopsy reports to identify rabies deaths. 1739 (93.65%) persons bitten by rabid- and 1066 (72.96%) bitten by sick-looking but untested dogs were traced and 513 were lost to follow-up. Among the former, 1591 (91.49%) and 129 (7.42%) patients referred for 4+ and 3 post-exposure prophylaxis sessions, respectively. Three persons died of probable rabies so that the overall percentage of survival was 99.83% (95% exact confidence interval: 99.49-99.96%) in post-exposure prophylaxis recipients bitten by confirmed rabid dogs. No significant difference was found in survival among patients who received 3 vs. 4+ sessions (with or without rabies immunoglobin). The power of the study, however, was limited. The current four sessions/one month intradermal regimen can be reduced to a three sessions/one week at no detectable added risk to patients, with the limitation of study power at 49%. A clinical follow-up system should be adopted by rabies prevention centers, especially to monitor implementation of an abridged course. The Institut Pasteur in Cambodia regimen will improve vaccine equity by treating 33% more patients with available doses, reduce direct cost of vaccination, transportation and other indirect costs to vaccinees.

Identifiants

pubmed: 30454946
pii: S0264-410X(18)31420-8
doi: 10.1016/j.vaccine.2018.10.054
pii:
doi:

Substances chimiques

Rabies Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

A118-A127

Informations de copyright

Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Arnaud Tarantola (A)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia; Epidemiology Unit, Institut Pasteur de Nouvelle-Calédonie, Nouméa, New Caledonia. Electronic address: arnaud.tarantola@pasteur.fr.

Sowath Ly (S)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Malen Chan (M)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Sotheary In (S)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Yiksing Peng (Y)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Chanthy Hing (C)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Chun Navy Taing (CN)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Chandara Phoen (C)

Epidemiology & Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Sovann Ly (S)

Center for Communicable Disease Control, Ministry of Health, Phnom Penh, Cambodia.

Simon Cauchemez (S)

Mathematical Modelling of Infectious Diseases Unit, CNRS UMR2000: Génomique évolutive, modélisation et santé (GEMS), Center of Bioinformatics, Biostatistics and Integrative Biology, Institut Pasteur, Paris 75015, France.

Philippe Buchy (P)

GlaxoSmithKline, Vaccines R&D, Singapore.

Philippe Dussart (P)

Virology Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Hervé Bourhy (H)

Institut Pasteur, Lyssavirus Dynamics and Host Adaptation Unit, WHO Collaborating Centre for Reference and Research on Rabies, Paris, France.

Jean-Yves Mary (JY)

Inserm UMR 1153, Centre de Recherche Epidémiologie et Statistique Sorbonne Paris Cité, Hôpital Saint-Louis, Université Paris Diderot - Paris 7, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH